Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05030246
Other study ID # 2021-012-CH04 IIT-GI
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 14, 2021
Est. completion date July 30, 2023

Study information

Verified date July 2021
Source Peking University
Contact Lin Shen, MD
Phone 86-10-88196561
Email linshenpku@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Surufatinib combined with Toripalimab in patients with peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer.


Description:

The study population is about 72 patients with advanced peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer, who fails or cannot tolerate standard therapies. Surufatinib 250 mg once a day (QD) will be orally administrated and Toripalimab 240mg will be intravenously administered every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. For Toripalimab, the upper time limit for treatment is 2 years. The primary objective is overall survival (OS) of Surufatinib combined with Toripalimab in patients with advanced solid advanced peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date July 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically or cytologically confirmed advanced peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer 2. Failed after standard treatment 3. Have evaluable lesions, including those that are not measurable 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 5. Adequately understand the study and voluntarily sign the Informed Consent Form; 6. =18 years old; 7. Lab tests within 7 days before first dose: 1) Absolute neutrophil count (ANC) =1.5×109/L, platelet count =100×109/L, and hemoglobin =100g/L; 2) Serum total bilirubin =1.5 times the upper limit of normal (ULN); 3) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels =2.5 times the ULN; 4) Patients without anticoagulant therapy: International Normalized Ratio (INR) =1.5 ULN and activated partial thromboplastin time (APTT) =1.5 ULN. If patients received anticoagulant therapy: INR =2 ULN and APTT was within the normal range 14 days before treatment; 5) Serum total bilirubin <1.5 times the upper limit of normal (ULN); 6) Urine protein < 2+; if =2+, 24-hour urine protein <1 g; 8. Male or females patients with reproductive potential must agree to use an effective contraceptive method, for example, double-barrier device, condom, oral or injected birth control medication or intrauterine device, during the study and within 90 days after study treatment discontinuation. All female patients are considered to be fertile, unless the patient had natural menopause or artificial menopause or sterilization (such as hysterectomy, bilateral oophorectomy or ovarian irradiation). Exclusion Criteria: 1. Prior system treatment with antiPD1/PDL1/PDL2/CTLA-4 antibody or Sulfatinib; 2. Previous intraperitoneal treatment with immunologic agents; 3. Patients with digestive tract obstruction or uncontrolled active bleeding from the primary tumor; 4. Patients with any active autoimmune disease or a documented history of autoimmune disease: Patients with hypothyroidism but receiving a stable dose of thyroid hormone replacement therapy were included in the study, and subjects with stable type 1 diabetes were able to control their blood sugar; 5. Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severe impaired lung function, etc; 6. Prior major surgery within past 4 weeks and had not fully recovered from previous surgery; 7. Active bleeding or abnormal coagulation, Prone to bleeding or receiving thrombolytic or anticoagulant therapy; 8. Hypertension that is not controlled by the drug, and is defined as: SBP=140 mmHg and/or DBP=90 mmHg; 9. Prior antitumor therapy (including chemotherapy, immunotherapy, biological treatment, Targeted therapy, etc) , or have not recovered from toxicities since the last treatment; 10. Pregnant or nursing; 11. previously received allogeneic stem cell or parenchymal organ transplantation; 12. Any significant clinical or laboratory abnormality that the investigator considers to influence the safety evaluators; 13. History of uncorrected serum electrolyte disturbances such as potassium, calcium, or magnesium; 14. Known human immunodeficiency virus (HIV) infection; 15. Active hepatitis B virus (HBV) and hepatitis C virus (HCV) infected persons; 16. A history of other malignancies within 5 years prior to inclusion, except for cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery; 17. Prior treatment with corticosteroids (dose > 10 mg/day prednisone or other hormones) or other immunosuppressive agents within 2 weeks, nasal or inhalation in allowed (dose > 10 mg/day prednisone or other hormones); 18. Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, LVEF <50%, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm); 19. History with tuberculosis who are receiving or have received anti-TB treatment within 1 year; 20. Active infection; 21. Receiving another experimental drug or participating in a clinical study for another therapeutic purpose within the first 28 days prior to treatment initiation; 22. Any other disease, metabolic disorder, abnormal results of a physical examination or laboratory examination, and reasonably suspected disease or condition that may contraindication the use of the investigational drug, or affect the reliability of the study results, or place the patient at high risk for treatment complications, or affect patient compliance.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Surufatinib/Toripalimab
Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival (OS) Duration from the date of initial treatment with Surufatinib plus toripalimab to the date of death due to any cause. From date of first dose of study drug until withdrawal of consent or death (up to approximately 1 year)
Secondary Progression-free Survival (PFS) A duration from the date of initial treatment with Surufatinib combined with Toripalimab to disease progression or death of any cause. From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 1 year)
Secondary adverse events Adverse events assessments are computed and categorized according to the Common Toxicity Criteria of the National Cancer Institute, version 5.0 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03393884 - Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) Phase 1/Phase 2
Completed NCT04546373 - Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Active, not recruiting NCT05456685 - IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer Phase 2
Recruiting NCT05494580 - Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Phase 1/Phase 2
Completed NCT02928549 - Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
Completed NCT02480374 - Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer Phase 1
Completed NCT01899599 - PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Phase 2
Completed NCT01219777 - Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian Phase 1
Completed NCT00959582 - Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) Phase 1
Terminated NCT00418093 - Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma Phase 2
Completed NCT00314678 - Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer Phase 2
Not yet recruiting NCT04889495 - A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Completed NCT01666444 - VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Phase 2
Recruiting NCT05665023 - Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma Phase 2
Terminated NCT01744821 - Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer N/A
Active, not recruiting NCT01220154 - Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer Phase 1
Completed NCT03213964 - Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int Phase 1
Not yet recruiting NCT06063070 - First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer Phase 2
Completed NCT01253681 - Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer Phase 1
Completed NCT01204749 - TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Phase 3